Child Asthma Attacks: Treatment Overview | Cochrane Reviews
- For children battling severe asthma attacks that don't respond to standard treatments, intravenous magnesium sulfate could reduce the duration of their hospital stay, according to a recent overview...
- The research, encompassing 13 Cochrane systematic reviews, sought to identify the most effective and safe interventions for children whose acute asthma symptoms persist despite first-line treatments like inhaled...
- While intravenous magnesium sulfate showed promise in reducing hospital stays, the analysis found no conclusive evidence that any treatment option definitively reduced the risk of admission to intensive...
For children experiencing severe asthma attacks,intravenous magnesium sulfate may shorten hospital stays,reveals a recent Cochrane review overview. This analysis of second-line treatments found no definitive best option too prevent intensive care admissions, but certain therapies show promise.inhaled anticholinergics, intravenous magnesium sulfate, and helium-oxygen mixtures might decrease the risk of hospital admission. Aminophylline carries a higher risk of nausea and vomiting, while anticholinergics could reduce tremors and nausea. The quality of evidence varies, underscoring the need for more extensive studies. news Directory 3 keeps you informed on the latest medical breakthroughs.Discover what’s next in asthma treatment research.
Second-Line Asthma Treatment Options for Children Examined
Updated June 2, 2025
For children battling severe asthma attacks that don’t respond to standard treatments, intravenous magnesium sulfate could reduce the duration of their hospital stay, according to a recent overview of studies. The analysis examined various second-line asthma treatment options, those used when initial treatments prove insufficient.
The research, encompassing 13 Cochrane systematic reviews, sought to identify the most effective and safe interventions for children whose acute asthma symptoms persist despite first-line treatments like inhaled bronchodilators and oral steroids. The review considered inhaled medications, intravenous drugs, and other therapies.
While intravenous magnesium sulfate showed promise in reducing hospital stays, the analysis found no conclusive evidence that any treatment option definitively reduced the risk of admission to intensive care. However, certain treatments appeared to decrease the likelihood of hospital admission, including the addition of an anticholinergic medication like ipratropium bromide to standard inhaled bronchodilator therapy, intravenous magnesium sulfate, and a helium-oxygen mixture.
The review also highlighted potential side effects associated with some treatments. Aminophylline, another bronchodilator administered intravenously, was linked to a higher incidence of nausea and vomiting. Conversely, adding an anticholinergic medication to inhaled bronchodilators appeared to reduce the risk of nausea and tremors, but not vomiting.
the quality of the evidence varied across the reviews,with many results stemming from small studies. Researchers emphasized the need for larger, multi-center studies to strengthen the evidence base and facilitate more confident recommendations for clinical practice.They also called for standardized measurement of results across studies to improve comparability.
One major hurdle in asthma treatment research is the relatively small number of patients included in individual studies, likely due to the uncommon nature of severe acute asthma in children. Researchers say that to determine if a treatment is effective, studies must include enough patients receiving each treatment.
What’s next
Future research should focus on large, collaborative studies employing standardized outcome measures to identify optimal second-line asthma treatment options for children and improve their care.